Betta Pharmaceuticals Co Ltd
SZSE:300558
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
45.55
74.97
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Betta Pharmaceuticals Co Ltd
EPS (Diluted)
Betta Pharmaceuticals Co Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Betta Pharmaceuticals Co Ltd
SZSE:300558
|
EPS (Diluted)
ÂĄ0
|
CAGR 3-Years
30%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
EPS (Diluted)
ÂĄ0
|
CAGR 3-Years
20%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
EPS (Diluted)
ÂĄ4
|
CAGR 3-Years
-1%
|
CAGR 5-Years
9%
|
CAGR 10-Years
17%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
EPS (Diluted)
ÂĄ1
|
CAGR 3-Years
26%
|
CAGR 5-Years
4%
|
CAGR 10-Years
14%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
EPS (Diluted)
ÂĄ2
|
CAGR 3-Years
25%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
1%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
EPS (Diluted)
ÂĄ9
|
CAGR 3-Years
N/A
|
CAGR 5-Years
241%
|
CAGR 10-Years
N/A
|
|
Betta Pharmaceuticals Co Ltd
Glance View
Betta Pharmaceuticals Co Ltd., established in 2003, is a dynamic player in China's rapidly evolving pharmaceutical landscape. The company made its mark with a particular focus on the research, development, production, and sale of innovative oncology drugs. Its flagship product, icotinib, a breakthrough therapy for non-small cell lung cancer, propelled Betta Pharmaceuticals into the spotlight, underpinning their pursuit of excellence in targeted cancer treatment. By capitalizing on expertise in small molecule drug discovery, Betta Pharmaceuticals transformed from a bold idea into a critical partner for healthcare providers, offering proprietary products that serve unmet medical needs across China and beyond. Driving its business model is a robust pipeline fueled by an ongoing commitment to research and innovation. Betta Pharmaceuticals thrives on its biodiverse R&D programs which are facilitated through collaborations with world-class research institutes and industry partners. The company's revenues predominantly flow from sales of its own branded oncology drugs, supplemented by royalty streams from licensing agreements. Their approach blends a careful balance of keen scientific inquiry with commercial acumen, as Betta continually reinvests in clinical trials and regulatory approvals to bring new drugs to market. Thus, the company's ability to blend innovation with practical application keeps it well-positioned amid the competitive and ever-evolving global pharmaceutical arena.
See Also
What is Betta Pharmaceuticals Co Ltd's EPS (Diluted)?
EPS (Diluted)
0.7
CNY
Based on the financial report for Sep 30, 2025, Betta Pharmaceuticals Co Ltd's EPS (Diluted) amounts to 0.7 CNY.
What is Betta Pharmaceuticals Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-12%
Over the last year, the EPS (Diluted) growth was -35%. The average annual EPS (Diluted) growth rates for Betta Pharmaceuticals Co Ltd have been 30% over the past three years , -12% over the past five years .